Merodantoin

CAS No. 143413-73-4

Merodantoin( —— )

Catalog No. M27994 CAS No. 143413-73-4

Merodantoin is an apoptosis inducer and triggers cell apoptosis associated with ROS-dependent autophagy. Merodantoin targets cancer cells expressing KRAS mutations involved in Akt-dependent ROS production.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 133 In Stock
5MG 149 In Stock
10MG 220 In Stock
25MG 337 In Stock
50MG 462 In Stock
100MG 619 In Stock
200MG 835 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Merodantoin
  • Note
    Research use only, not for human use.
  • Brief Description
    Merodantoin is an apoptosis inducer and triggers cell apoptosis associated with ROS-dependent autophagy. Merodantoin targets cancer cells expressing KRAS mutations involved in Akt-dependent ROS production.
  • Description
    Merodantoin is an apoptosis inducer and triggers cell apoptosis associated with ROS-dependent autophagy. Merodantoin targets cancer cells expressing KRAS mutations involved in Akt-dependent ROS production.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Apoptosis
  • Target
    Apoptosis
  • Recptor
    cereblon (CRBN) E3 ligase
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    143413-73-4
  • Formula Weight
    242.34
  • Molecular Formula
    C11H18N2O2S
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    CCCCN1C(=O)C(=O)N(CCCC)C1=S
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.David Proia, et al. Advantageous therapies for disorders mediated by ikaros or aiolos. WO2022032132A1.
molnova catalog
related products
  • CDK8-IN-13

    CDK8-IN-13 is a CDK8 inhibitor (IC50: 51.9 nM) with potent, selective and oral activity. CDK8-IN-13 induces apoptosis and reduces the expression of p-STAT1 S727 and p-STAT5 S726. CDK8-IN-13 exhibits anti-tumour activity.

  • (E/Z)-E64FC26

    (E/Z)-E64FC26 is a potent protein disulfide isomerase (PDI) family inhibitor with potential antitumor activity and affinity for PDIA1, PDIA3, PDIA4, TXNDC5 and PDIA6. (E/Z)-E64FC26 can be used for myeloma research.

  • Rigosertib

    Rigosertib is a selective and non-ATP-competitive inhibitor of PLK1 (IC50: 9 nM).